

Rebecca L Haffajee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7239745/publications.pdf>

Version: 2024-02-01

21
papers

1,393
citations

623734

14
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

1960
citing authors

#	ARTICLE	IF	CITATIONS
1	An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 57-58.	3.9	278
2	Thinking Globally, Acting Locally – The U.S. Response to Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, e75.	27.0	222
3	Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. <i>JAMA Network Open</i> , 2019, 2, e196373.	5.9	187
4	Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. <i>American Journal of Preventive Medicine</i> , 2018, 54, S230-S242.	3.0	177
5	Qualifying Conditions Of Medical Cannabis License Holders In The United States. <i>Health Affairs</i> , 2019, 38, 295-302.	5.2	139
6	Association of State Opioid Duration Limits With Postoperative Opioid Prescribing. <i>JAMA Network Open</i> , 2019, 2, e1918361.	5.9	55
7	Drug Companies’ Liability for the Opioid Epidemic. <i>New England Journal of Medicine</i> , 2017, 377, 2301-2305.	27.0	54
8	Trends in Suicidality 1 Year Before and After Birth Among Commercially Insured Childbearing Individuals in the United States, 2006-2017. <i>JAMA Psychiatry</i> , 2021, 78, 171.	11.0	49
9	Making the Opioid Public Health Emergency Effective. <i>JAMA Psychiatry</i> , 2018, 75, 767.	11.0	38
10	The Association of State Opioid Misuse Prevention Policies With Patient- and Provider-Related Outcomes: A Scoping Review. <i>Milbank Quarterly</i> , 2020, 98, 57-105.	4.4	37
11	Prescription Drug Monitoring Programs – Friend or Folly in Addressing the Opioid-Overdose Crisis?. <i>New England Journal of Medicine</i> , 2019, 381, 699-701.	27.0	35
12	Common themes in early state policy responses to substance use disorder treatment during COVID-19. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 486-496.	2.1	26
13	Behind Schedule – Reconciling Federal and State Marijuana Policy. <i>New England Journal of Medicine</i> , 2018, 379, 501-504.	27.0	20
14	Legal requirements and recommendations to prescribe naloxone. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107896.	3.2	17
15	Pregnant Women with Substance Use Disorders – The Harm Associated with Punitive Approaches. <i>New England Journal of Medicine</i> , 2021, 384, 2364-2367.	27.0	16
16	Provider perceptions of system-level opioid prescribing and addiction treatment policies. <i>Current Opinion in Psychology</i> , 2019, 30, 65-73.	4.9	13
17	Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids. <i>JAMA Network Open</i> , 2019, 2, e193673.	5.9	11
18	Abuses of FDA Regulatory Procedures – The Case of Suboxone. <i>New England Journal of Medicine</i> , 2020, 382, 496-498.	27.0	10

#	ARTICLE	IF	CITATIONS
19	Opioid prescribing history prior to heroin overdose among commercially insured adults. <i>Drug and Alcohol Dependence</i> , 2020, 212, 108061.	3.2	6
20	Association of Federal Mental Health Parity Legislation With Health Care Use and Spending Among High Utilizers of Services. <i>Medical Care</i> , 2019, 57, 245-255.	2.4	2
21	The Trump Administration's Actions to Address the Opioids Public Health Crisis—Reply. <i>JAMA Psychiatry</i> , 2019, 76, 101.	11.0	1